Search

Your search keyword '"Moeller F"' showing total 737 results
Start Over Author "Moeller F" Publication Type Academic Journals
737 results on '"Moeller F"'

5. Cingulo-hippocampal effective connectivity positively correlates with drug-cue attentional bias in opioid use disorder.

Author

Ma, Liangsuo, Steinberg, Joel L, Bjork, James M, Taylor, Brian A, Arias, Albert J, Terplan, Mishka, Anastasio, Noelle C, Zuniga, Edward A, Lennon, Michael, Cunningham, Kathryn A, and Moeller, F Gerard

Subjects
Brain, Gyrus Cinguli, Hippocampus, Temporal Lobe, Humans, Opioid-Related Disorders, Analgesics, Opioid, Magnetic Resonance Imaging, Brain Mapping, Cognition, Cues, Reaction Time, Female, Male, Stroop Test, Attentional Bias, Attentional bias, Cue reactivity, Dynamic causal modeling, Effective connectivity, Opioid use disorder, Neurosciences, Clinical Research, Brain Disorders, Behavioral and Social Science, Substance Misuse, Basic Behavioral and Social Science, Drug Abuse (NIDA only), Mental health, Clinical Sciences, Cognitive Sciences, Psychiatry
Abstract

Individuals with opioid use disorder (OUD) often relapse when exposed to opioid-related cues. Previous functional magnetic resonance imaging (fMRI) studies have identified neuronal corticolimbic changes related to drug cue reactivity in OUD. However, the corresponding manner in which brain regions interact is still unclear. Effective (directional) connectivity was analyzed using dynamic causal modeling of fMRI data acquired from 27 OUD participants (13 with OUD and 14 with OUD and cocaine use disorder [OUD+CUD]), while performing an opioid-word Stroop task. Participants were shown opioid and neutral words presented in different colors and were instructed to indicate word color but ignore word meaning. The effects of opioid words relative to neutral words on effective connectivity and on behavioral reaction time were defined as modulatory change and attentional bias, respectively. For all the 27 participants, left anterior cingulate cortex (ACC) to right hippocampus effective connectivity exhibited the largest modulatory change, which was positively correlated with attentional bias. The findings for the ACC to hippocampus EC were consistent across OUD and CUD found in a previous study.

Published
2019

14. Insomnia symptoms and neurofunctional correlates among adults receiving buprenorphine for opioid use disorder.

Author

White, Augustus M., Eglovitch, Michelle, Parlier-Ahmad, Anna Beth, Dzierzewski, Joseph M., James, Morgan, Bjork, James M., Moeller, F. Gerard, and Martin, Caitlin E.

Subjects
INTEROCEPTION, OPIOID abuse, INSOMNIA, SLEEP interruptions, BUPRENORPHINE, ADULTS, MORBID obesity
Abstract

Objectives: Insomnia symptoms are negatively related to opioid use disorder (OUD) treatment outcomes, possibly reflecting the influence of sleep on neurofunctional domains implicated in addiction. Moreover, the intersection between OUD recovery and sleep represents an area well-suited for the development of novel, personalized treatment strategies. This study assessed the prevalence of clinically significant insomnia symptoms and characterized its neurofunctional correlates among a clinical sample of adults with OUD receiving buprenorphine. Methods: Adults (N = 129) receiving buprenorphine for OUD from an outpatient clinic participated in a cross-sectional survey. Participants completed an abbreviated version of NIDA's Phenotyping Assessment Battery, which assessed 6 neurofunctional domains: sleep, negative emotionality, metacognition, interoception, cognition, and reward. Bivariate descriptive statistics compared those with evidence of clinically significant insomnia symptoms (Insomnia Severity Index [ISI] score of ≥11) to those with minimal evidence of clinically significant insomnia symptoms (ISI score of ≤10) across each of the neurofunctional domains. Results: Roughly 60% of participants reported clinically significant insomnia symptoms (ISI score of ≥11). Experiencing clinically significant insomnia symptoms was associated with reporting greater levels of depression, anxiety, post-traumatic stress, stress intolerance, unhelpful metacognition, and interoceptive awareness (ps<0.05). Participants with evidence of clinically significant insomnia were more likely to report that poor sleep was interfering with their OUD treatment and that improved sleep would assist with their treatment (ps<0.05). Conclusions: Insomnia was prevalent among adults receiving buprenorphine for OUD. Insomnia was associated with neurofunctional performance, which may impact OUD treatment trajectories. Our findings indicate potential targets in the development of personalized treatment plans for patients with co-morbid insomnia and OUD. To inform the development of novel treatment strategies, more research is needed to understand the potential mechanistic links between sleep disturbances and substance use. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Measures of outcome for stimulant trials: ACTTION recommendations and research agenda

Author

Kiluk, Brian D, Carroll, Kathleen M, Duhig, Amy, Falk, Daniel E, Kampman, Kyle, Lai, Shengan, Litten, Raye Z, McCann, David J, Montoya, Ivan D, Preston, Kenzie L, Skolnick, Phil, Weisner, Constance, Woody, George, Chandler, Redonna, Detke, Michael J, Dunn, Kelly, Dworkin, Robert H, Fertig, Joanne, Gewandter, Jennifer, Moeller, F Gerard, Ramey, Tatiana, Ryan, Megan, Silverman, Kenneth, and Strain, Eric C

Subjects
Drug Abuse (NIDA only), Neurosciences, Prevention, Clinical Trials and Supportive Activities, Clinical Research, Brain Disorders, Substance Misuse, Alcoholism, Alcohol Use and Health, Good Health and Well Being, Amphetamine-Related Disorders, Central Nervous System Stimulants, Clinical Trials as Topic, Congresses as Topic, Humans, Practice Guidelines as Topic, Substance-Related Disorders, Treatment Outcome, Stimulant use disorders, Outcome measures, Clinical trials, Medical and Health Sciences, Psychology and Cognitive Sciences, Substance Abuse
Abstract

BackgroundThe development and approval of an efficacious pharmacotherapy for stimulant use disorders has been limited by the lack of a meaningful indicator of treatment success, other than sustained abstinence.MethodsIn March, 2015, a meeting sponsored by Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) was convened to discuss the current state of the evidence regarding meaningful outcome measures in clinical trials for stimulant use disorders. Attendees included members of academia, funding and regulatory agencies, pharmaceutical companies, and healthcare organizations. The goal was to establish a research agenda for the development of a meaningful outcome measure that may be used as an endpoint in clinical trials for stimulant use disorders.Results and conclusionsBased on guidelines for the selection of clinical trial endpoints, the lessons learned from prior addiction clinical trials, and the process that led to identification of a meaningful indicator of treatment success for alcohol use disorders, several recommendations for future research were generated. These include a focus on the validation of patient reported outcome measures of functioning, the exploration of patterns of stimulant abstinence that may be associated with physical and/or psychosocial benefits, the role of urine testing for validating self-reported measures of stimulant abstinence, and the operational definitions for reduction-based measures in terms of frequency rather than quantity of stimulant use. These recommendations may be useful for secondary analyses of clinical trial data, and in the design of future clinical trials that may help establish a meaningful indicator of treatment success.

Published
2016

35. Measures of outcome for stimulant trials: ACTTION recommendations and research agenda

Author

Kiluk, Brian D., Carroll, Kathleen M., Duhig, Amy, Falk, Daniel E., Kampman, Kyle, Lai, Shengan, Litten, Raye Z., McCann, David J., Montoya, Ivan D., Preston, Kenzie L., Skolnick, Phil, Weisner, Constance, Woody, George, Chandler, Redonna, Detke, Michael J., Dunn, Kelly, Dworkin, Robert H., Fertig, Joanne, Gewandter, Jennifer, Moeller, F. Gerard, Ramey, Tatiana, Ryan, Megan, Silverman, Kenneth, and Strain, Eric C.

Published
2016
Full Text
View/download PDF

37. Ghrelin receptor antagonist JMV2959 blunts cocaine and oxycodone drug-seeking, but not self-administration, in male rats.

Author

Merritt, Christina R., Garcia, Erik J., Brehm, Victoria D., Fox, Robert G., Moeller, F. Gerard, Anastasio, Noelle C., and Cunningham, Kathryn A.

Subjects
GHRELIN receptors, APPETITE stimulants, COCAINE, OXYCODONE, DRUG overdose, SPRAGUE Dawley rats, MEDICATION therapy management
Abstract

The drug overdose crisis has spawned serious health consequences, including the increased incidence of substance use disorders (SUDs), conditions manifested by escalating medical and psychological impairments. While medication management is a key adjunct in SUD treatment, this crisis has crystallized the need to develop additional therapeutics to facilitate extended recovery from SUDs. The “hunger hormone” ghrelin acts by binding to the growth hormone secretagogue receptor 1α (GHS1αR) to control homeostatic and hedonic aspects of food intake and has been implicated in the mechanisms underlying SUDs. Preclinical studies indicate that GHS1αR antagonists and inverse agonists suppress reward-related signaling associated with cocaine and opioids. In the present study, we found that the GHS1αR antagonist JMV2959 was efficacious to suppress both cue-reinforced cocaine and oxycodone drug-seeking, but not cocaine or oxycodone self-administration in male Sprague-Dawley rats. These data suggest a role of the ghrelin-GHS1αR axis in mediating overlapping reward-related aspects of cocaine and oxycodone and premises the possibility that a GHS1αR antagonist may be a valuable therapeutic strategy for relapse vulnerability in SUDs. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

40. Evaluation of the dopamine β-hydroxylase (DβH) inhibitor nepicastat in participants who meet criteria for cocaine use disorder

Author

De La Garza, Richard, II, Bubar, Marcy J., Carbone, Crystal L., Moeller, F. Gerard, Newton, Thomas F., Anastasio, Noelle C., Harper, Tod A., Ware, David L., Fuller, Michael A., Holstein, Gaylyn J., Jayroe, Jason B., Bandak, Stephen I., Reiman, Kirsten Z., Neale, Ann C., Pickford, Lesley B., and Cunningham, Kathryn A.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results